CDER Takes A Micro/Macro Approach To Monitoring ‘Breakthrough’ Programs
Executive Summary
Agency staff will conduct high-level reviews every three to six months to assess adequacy of individual development programs, while the Medical Policy Council will undertake portfolio reviews across breakthrough-designated products.
You may also be interested in...
‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
ODAC Report Card: Six Takeaways From Accelerated Approval Reviews Of Checkpoint Inhibitors
US FDA’s expedited pathway remains alive and well in oncology, but ‘dangling’ indications may be subject to more regular public scrutiny going forward; negative votes for two of six indications reflected the influence of Oncology Center of Excellence director Richard Pazdur.